BioCatalyst

KYTX — Kyverna Therapeutics, Inc. catalysts

1 verified catalyst event(s) for Kyverna Therapeutics, Inc. (ticker KYTX). Each is linked to its official source. Verified as of 2026-06-22.

Next verified catalyst

2026-08-01 — KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Sub · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-08 (month)
in 1mo
ESTIMATED
 READOUT
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Thera
Phase 1/2 · Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III
 KYTX Kyverna Therapeutics, Inc. KYV-101 anti-CD19 CAR-T cell therapy, St ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.